Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.
Read MoreARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in 2021.
Read MoreARTIDIS announces its successful integration in the highly competitive international Medical Device Cohort 2019 of the Texas Medical Center's (TMC) Innovation Institute.
Read MoreSymphonyRM to help Intermountain Healthcare Kidney Services proactively engage, educate, and manage patients earlier in their journey to cut unnecessary hospital admissions by up to 50 percent
Read MoreFunding underscores healthcare's demand for the company's data science-driven CRM to deliver personalized, prioritized, and proactive consumer engagement
Read More